Publikacje
- Wszystkie
-
- Wszystkie
- Synthetic Lethality
- SEL24
- RVU120
- Wszystkie
-
- Wszystkie
- MEN1703 (SEL24)
- Novel Targets
- WRN
- PRMT5
- CDK8/CDK19
- HPK1
- SMARCA
- MNK
- GCN2
- SHMT
- STING
- A2A/A2B
- CDK8
- PIM/FLT3
-
AACR-NCI-EORTC International Conference (ENA) 2024, October 23-25, 2024
Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
Aby pobrać wybrany materiał, wypełnij poniższy formularz:
-
Discovery of novel MTA-cooperative PRMT5 preclinical candidate as targeted therapeutics for MTAP-deleted cancers
To download chosen material please fill in form below:
-
Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors
To download chosen material please fill in form below:
-
Exploring Synthetic Lethality and Novel Drug Combinations in Patient-Derived Cells
To download chosen material please fill in form below:
-
European Hematology Association (EHA) Congress, June 13 -16, 2024
RVU120, a first-in-class CDK8 inhibitor for the treatment of relapsed/refractory AML and high-risk MDS: preliminary results from two ongoing studies.
To download chosen material please fill in form below:
-
Synergistic potential of RVU120, a first-in-class CDK8/CDK19 inhibitor, with venetoclax in AML: preclinical and initial clinical insights.
To download chosen material please fill in form below:
-
CDK8/19 Inhibition: A Promising Therapeutic Strategy in Myeloproliferative Neoplasms.
To download chosen material please fill in form below:
-
American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024
Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers
To download chosen material please fill in form below:
-
Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors
To download chosen material please fill in form below:
-
A Comprehensive Platform for Identification of KRAS-specific Synthetic Lethal Targets using Patient-Derived Cells
To download chosen material please fill in form below:
-
MEN1703/SEL24 exhibits promising antitumoral activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
To download chosen material please fill in form below:
-
Combination JAK1/2 and CDK8/19 inhibition demonstrates enhanced efficacy in myeloproliferative neoplasms.
To download chosen material please fill in form below:
-
American Society of Hematology (ASH) Annual Meeting, December 9 –12, 2023
Safety and Efficacy Results from CLI120-001 a Phase 1 Study in RR-AML and HRMDS: Update from Higher Dose Levels
To download chosen material please fill in form below:
-
Preclinical and Clinical Evidence for Erythroid-Stimulating Activity of RVU120 CDK8/19 Inhibitor in AML and MDS
To download chosen material please fill in form below:
-
Novel Clinically Useful Inhibitor of Mediator Complex, RVU120, Relieves Differentiation Block in MDS/AML
To download chosen material please fill in form below:
-
Targeting CDK8/CDK19 to Disrupt Leukemic Stem Cell-like Population in Acute Myeloid Leukemia: Exploring RVU120 As a Promising Frontline Therapy
To download chosen material please fill in form below:
-
Mediator Kinase/CDK8 Inhibition as a Strategy to Improve FLT3 Inhibitor Activity in Acute Myeloid Leukemia
To download chosen material please fill in form below:
-
San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023
Synergistic Activity of CDK8/19 Inhibitor RVU120 and MEK Inhibitors in Hormone-Negative Breast Cancer: Implications for Targeted Therapy
To download chosen material please fill in form below:
-
European Society for Medical Oncology (ESMO) Congress 2023, October 20-24, 2023
Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor, in patients with relapsed/refractory metastatic or advanced solid tumors
To download chosen material please fill in form below:
-
AACR-NCI-EORTC International Conference (ENA) 2023, October 11-15, 2023
Discovery of Novel MTA-cooperative PRMT5 Inhibitors as Targeted Therapeutics for MTAP-deleted Cancers
To download chosen material please fill in form below:
-
Comprehensive Platform for Unraveling the Molecular Mechanisms and Vulnerabilities of Colorectal Cancer: A Step Forward in Target Discovery
To download chosen material please fill in form below:
-
MEN1703/SEL24, A Potent PIM Inhibitor, Demonstrates Promising Anti-Tumor Activity in Activated B Cell Like DLBCL, Mantle Cell Lymphoma and Marginal Zone Lymphoma Cells
To download chosen material please fill in form below:
-
Congress of the Polish Society of Hematology and Transfusion Medicine, September 14-16, 2023
Safety and Efficacy Update from CLI120–001: a Phase 1b Dose Escalation Study in Relapse-Refractory Acute Myeloid Leukemia and High-Risk Myelodysplasia
To download chosen material please fill in form below:
-
RVU120 CDK8/19 Inhibitor Promotes Erythroid Differentiation in AML and HR-MDS Patients
To download chosen material please fill in form below:
-
European Hematology Association (EHA) Hybrid Congress, June 8-11, 2023
Safety and efficacy update from CLI120-001: a Phase 1b dose-escalation study in relapse/refractory AML and HR-MDS
To download chosen material please fill in form below:
-
Combination JAK1/2 and CDK8/19 inhibition demonstrates enhanced efficacy in myeloproliferative neoplasms
To download chosen material please fill in form below:
-
American Association for Cancer Research (AACR) Annual Meeting, April 14-19, 2023
Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers
To download chosen material please fill in form below:
-
American Society of Hematology (ASH) Annual Meeting, December 10 –13, 2022
CDK8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts
To download chosen material please fill in form below:
-
Multiomics Analysis Confirms Effective Target Engagement for RVU120 – a First-in-class CDK8/19 Kinase Inhibitor in AML and MR-MDS Patients and Reveals the Mechanism of Action
To download chosen material please fill in form below:
-
PIM Inhibition by SEL24 (MEN1703) Combines Synergistically with gilteritinib in FLT3-ITD Preclinical Models of Acute Myeloid Leukemia
To download chosen material please fill in form below:
-
Super-enhancer-driven PIM Kinase Upregulation in Multiple Myeloma Maintains the Plasma Cell-specific Oncogenic and Microenvironmental Circuits and Can Be Efficiently Targeted by the Pan-PIM Inhibitor MEN1703
To download chosen material please fill in form below:
-
PIM Kinases Regulate Super-Enhancer-Dependent Gene Expression In Diffuse Large B-Cell Lymphoma
To download chosen material please fill in form below:
-
MEN1703-mediated PIM kinases inhibition impairs protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma
To download chosen material please fill in form below:
-
EORTC-NCI-AACR Symposium (ENA), October 26-28, 2022
Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
To download chosen material please fill in form below:
-
RVU120, a small molecule inhibitor of CDK8/19 kinases, enhances rituximab-driven NK cells-mediated cytotoxicity both in vitro and in vivo
To download chosen material please fill in form below:
-
Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP deleted cancers
To download chosen material please fill in form below:
-
European Hematology Association (EHA) Hybrid Congress, June 9-17, 2022
CLI120-001 Phase1b Dose Escalation Study of RVU120 in Patients with AML or High-Risk MDS Safety and Efficacy Data Update
To download chosen material please fill in form below:
-
Preclinical and Clinical Signs of RVU120 efficacy, a Specific CDK8/19 Inhibitor in DNMT3A and NPM1 Mutation Positive AML and HR-MDS
To download chosen material please fill in form below:
-
Phase 1/2 Study of SEL24/MEN1703, a First-In-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients with IDH1/2-Mutated Acute Myeloid Leukemia: the DIAMOND-01 Trial
To download chosen material please fill in form below:
-
American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022
Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: the DIAMOND-01 trial
To download chosen material please fill in form below:
-
Phase I/II trial of RVU120 (SEL120), a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
To download chosen material please fill in form below:
-
American Association for Cancer Research (AACR) Annual Meeting, April 8-13, 2022
"RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo"
To download chosen material please fill in form below:
-
"Discovery of novel MTA-cooperative PRMT5 inhibitors as a targeted therapeutic for MTAP deleted cancers"
To download chosen material please fill in form below:
-
"RVU120 SOL-021: An open-label, single agent, Phase I/II trial of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors"
To download chosen material please fill in form below:
-
63rd American Society of Hematology (ASH) Annual Meeting & Exposition, December 11 – 14, 2021
"CLI120-001 Phase Ib Study of RVU120 (SEL120) in Patients with AML and High-Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation"
To download chosen material please fill in form below:
-
"RVU120 – a CDK8/19 Inhibitor for the Treatment of AML and HR-MDS Can Induce Erythroid Differentiation"
To download chosen material please fill in form below:
-
"Inhibition of Cyclin Dependent Kinase 8 (CDK8): A Novel Approach to Target the Leukemia Initiating Cells (LICs) in T-Cell Acute Lymphoblastic Leukemia (T-ALL)"
To download chosen material please fill in form below:
-
"Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML"
To download chosen material please fill in form below:
-
"SEL24(MEN1703) Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial"
To download chosen material please fill in form below:
-
44th Annual San Antonio Breast Cancer Symposium (SABCS), December 7-10, 2021
"Selective CDK8/CDK19 inhibitor RVU120 demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo"
To download chosen material please fill in form below:
-
Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting, November 11-14, 2021
"Novel, orally administered HPK1 inhibitors demonstrate anti-tumor efficacy and enhanced immune response"
To download chosen material please fill in form below:
-
"Characterization of RVU-27065 a novel small-molecule STING agonist suitable for systemic administration"
To download chosen material please fill in form below:
-
Discovery of 5-{2-[5-Chloro-2-(5-ethoxyquinoline-8-sulfonamido)phenyl]ethynyl}-4-methoxypyridine-2-carboxylic Acid, a Highly Selective in Vivo Useable Chemical Probe to Dissect MCT4 Biology
Heinrich T, Sala-Hojman A, Ferretti R, Petersson C, Minguzzi S, Gondela A, Ramaswamy S, Bartosik A et al. Discovery of 5-{2-[5-Chloro-2-(5-ethoxyquinoline-8-sulfonamido)phenyl]ethynyl}-4-methoxypyridine-2-carboxylic Acid, a Highly Selective in Vivo Useable Chemical Probe to Dissect MCT4 Biology. Journal of Medicinal Chemistry, August 2021
To download chosen material please fill in form below:
-
Virtual 26th Annual European Hematology Association (EHA) Congress, June 9-17, 2021
"RVU120/SEL120 CDK8/19 inhibitor - a drug candidate for the treatment of MDS can induce erythroid differentiation in transformed CD34+ hematopoietic progenitor cells"
To download chosen material please fill in form below:
-
"CLI120-001 Phase 1b Study of SEL120/RVU120 in patients with AML or High Risk MDS: Preliminary clinical and PK results from initial dose escalation cohorts"
To download chosen material please fill in form below:
-
“Results from DIAMOND-01 (CLI24-001) TRIAL: First in Human Study of SEL24/MEN1703, a Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia”
To download chosen material please fill in form below:
-
AACR Virtual Annual Meeting 2021, April 10-15 and May 17-21, 2021
"RVU120 (SEL120), a CDK8/CDK19 inhibitor, possesses strong multilineage differentiation potential in leukemic cells"
To download chosen material please fill in form below:
-
"Development and characterization of small molecule HPK1 inhibitors"
To download chosen material please fill in form below:
-
"New generation of STING agonists: development and characterization of a novel series of systemic immunomodulators with improved potency"
To download chosen material please fill in form below:
-
62nd American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2020
"SEL24/MEN1703 provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamic (PD) Assay in the Dose Escalation Part of First-in-Human DIAMOND-01 Trial"
To download chosen material please fill in form below:
-
"PIM Kinase Inhibition Decreases the Proangiogenic Properties of Multiple Myeloma Cells and Affects the Metabolic State of the Vascular Endothelium"
To download chosen material please fill in form below:
-
Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting, November 11-14, 2020
"Development of improved small molecule STING agonists suitable for systemic administration"
To download chosen material please fill in form below:
-
AACR Virtual Annual Meeting II, June 22-24, 2020
"Synergistic effect of CDK8 and BCL-2 inhibition in AML through regulation of MCL-1 and BIM balance"
To download chosen material please fill in form below:
-
"In vivo and in vitro characterization of RVU330 best-in-class dual A2A/A2B adenosine receptor antagonist"
To download chosen material please fill in form below:
-
"Development of selective small molecule STING agonists suitable for systemic administration"
To download chosen material please fill in form below:
-
"Development and characterization of small molecule HPK1 inhibitors"
To download chosen material please fill in form below:
-
"Development of novel, selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1) mutated tumors"
To download chosen material please fill in form below:
-
Virtual 25th Annual European Hematology Association (EHA) Congress, June 11-21, 2020
“A First-in-human study of SEL120, a novel oral selective CDK8/19 inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome”
To download chosen material please fill in form below:
-
"Results of the dose escalation part of DIAMOND trial (CLI24-001): first in human study of SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor, in Patients with Acute Myeloid Leukemia"
To download chosen material please fill in form below:
-
Synthetically Lethal Interactions of Heme Oxygenase-1 and Fumarate Hydratase Genes
Podkalicka, P.; Mucha, O.; Kruczek, S.; Biela, A.; Andrysiak, K.; Stępniewski, J.; Mikulski, M.; Gałęzowski, M.; Sitarz, K.; Brzózka, K.; Józkowicz, A.; Dulak, J.; Łoboda, A. Synthetically Lethal Interactions of Heme Oxygenase-1 and Fumarate Hydratase Genes. Biomolecules 2020, 10, 143.
To download chosen material please fill in form below:
-
61st American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, Orlando, FL, USA
"SEL120 – a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial"
To download chosen material please fill in form below:
-
"CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation"
To download chosen material please fill in form below:
-
Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019), November 6–10, National Harbor, MD, USA
"Novel dual A2A /A2B adenosine receptor antagonists for cancer immunotherapy in vitro characterization"
To download chosen material please fill in form below:
-
"Development and characterization of next generation small molecule STING agonists"
To download chosen material please fill in form below:
-
CICON 2019 – Translating Science into Survival – September 25-28, 2019, Paris, France
“Characterization of novel potent dual A2A/A2B adenosine receptor antagonists for cancer immunotherapy”
To download chosen material please fill in form below:
-
24th Congress of EHA, June 13-16, 2019 Amsterdam, Netherlands
"CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia"
To download chosen material please fill in form below:
-
ASCO Annual Meeting 2019, May 31-June 4, Chicago, IL, USA
"CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia"
To download chosen material please fill in form below:
-
AACR Annual Meeting 2019, March 29- April 3, 2019, Atlanta, GA, USA
"SEL120, a Potent and Specific Inhibitor of CDK8 Induces Complete Remission in Human Patient Derived Xenograft Models of Acute Myeloid Leukemia (AML)"
To download chosen material please fill in form below:
-
"Novel dual A2A /A2B adenosine receptor antagonists for cancer immunotherapy in vitro and in vivo characterization"
To download chosen material please fill in form below:
-
"Discovery and characterization of next-generation small molecule direct STING agonists"
To download chosen material please fill in form below:
-
American Society of Hematology (ASH) Annual Meeting, 1-4 December 2018, San Diego, CA, USA
"CDK8 Inhibitor SEL120-34A Has Therapeutic Efficacy in Murine and Human AML Models"
To download chosen material please fill in form below:
-
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, 13-16 November 2018, Dublin, Ireland
“SEL120−34A, a potent and specific inhibitor of CDK8, as a potential treatment of acute myeloid and lymphoblastic leukemias”
To download chosen material please fill in form below:
-
Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC), 7-11 November 2018, Washington, DC, USA
"Novel class of small molecule direct STING agonists as a potential cancer immunotherapy"
To download chosen material please fill in form below:
-
“Characterization of novel dual A2A/B adenosine receptor antagonists for cancer immunotherapy”
To download chosen material please fill in form below:
-
Mechanisms to Therapies: Innovations in Cancer Metabolism, 9-11 October 2018, Bilbao, Spain
"Discovery of novel SHMT1/2 small molecule inhibitors for cancer treatment"
To download chosen material please fill in form below:
-
Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice, 3-5 October 2018, Dubrovnik, Croatia
“CDK8 inhibitor SEL120 targets AML by regulation of transcriptional programs involved in the maintenance of leukemia stem cells”
To download chosen material please fill in form below:
-
Annual Immuno-Oncology Summit, 27-31 August 2018, Boston, MA, USA
"Discovery of novel small molecule STING agonists as a new cancer immunotherapy"
To download chosen material please fill in form below:
-
“Characterization of novel dual A2A/B adenosine receptor antagonists for cancer immunotherapy”
To download chosen material please fill in form below:
-
AACR Annual Meeting 2018, 14-18 April 2018, Chicago, IL, USA
"Characterization of novel dual A2A/A2B adenosine receptor antagonists for cancer immunotherapy"
To download chosen material please fill in form below:
-
"CDK8 inhibitor SEL120-34A targets CD34 positive AML cells by regulation of transcriptional programs involved in the maintenance of leukemia stem cells"
To download chosen material please fill in form below:
-
"Discovery of novel SHMT small molecule inhibitors for cancer treatment"
To download chosen material please fill in form below:
-
AACR Annual Meeting 2017, 1 - 5 April 2017, Washington, DC, USA
"Development of small molecule selective inhibitors of GCN2 as an immunotherapy aimed at preventing immune escape of tumor cells"
To download chosen material please fill in form below:
-
"Differential activity on lung adenocarcinoma cells with loss-of-function mutations of SWI/SNF protein SMARCA4"
To download chosen material please fill in form below:
-
"Small molecule inhibitors of SHMT1/2 validate serine metabolism as a target in the treatment of c-Myc positive solid tumors"
To download chosen material please fill in form below:
-
"Inhibition of CDK8 kinase with SEL120-34A allows for a personalized approach in AML"
To download chosen material please fill in form below:
-
"Development of a potent, dual pan-PIM/FLT3 inhibitor for the treatment of heme malignancies"
To download chosen material please fill in form below:
-
AACR Annual Meeting 2015, 18 – 22 April 2015 in Philadelphia, PA, USA:
“First-in-class dual PIM/FLT3 inhibitor SEL24-B489 for the treatment of hematological malignancies”
To download chosen material please fill in form below:
-
“Selective CDK8 inhibitor SEL120-34A alters expression of interferon-related DNA damage resistance signature genes in colorectal cancer”
To download chosen material please fill in form below:
-
AACR Annual Meeting 2014, 5-9 April 2014, San Diego, USA:
“Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies”
To download chosen material please fill in form below:
-
“Repression of tumor survival pathways by novel, selective inhibitors of MNK1 and MNK2 kinases”
To download chosen material please fill in form below:
